{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:12:07Z","timestamp":1787242327308,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015401","name":"Shaanxi Province Key Research and Development Projects","doi-asserted-by":"publisher","award":["2023ZDLSF-33"],"award-info":[{"award-number":["2023ZDLSF-33"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015401","name":"Shaanxi Province Key Research and Development Projects","doi-asserted-by":"publisher","award":["2021ZDLSF02-07"],"award-info":[{"award-number":["2021ZDLSF02-07"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81820108005"],"award-info":[{"award-number":["81820108005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81900502"],"award-info":[{"award-number":["81900502"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200577"],"award-info":[{"award-number":["82200577"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173241"],"award-info":[{"award-number":["82173241"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.dld.2024.12.024","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T07:25:28Z","timestamp":1736753128000},"page":"861-868","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The prognostic value of anti-gp210 and anti-centromere antibodies in patients with primary biliary cholangitis: Enhancing the prognostic utility on the GLOBE scoring system"],"prefix":"10.1016","volume":"57","author":[{"given":"Dawei","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yansheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanya","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3046-9507","authenticated-orcid":false,"given":"Ying","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.dld.2024.12.024_bib0001","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1053\/gast.2002.36027","article-title":"Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years","volume":"123","author":"Prince","year":"2002","journal-title":"Gastroenterology"},{"issue":"10266","key":"10.1016\/j.dld.2024.12.024_bib0002","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(20)31607-X","article-title":"Primary biliary cholangitis","volume":"396","author":"Lleo","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.dld.2024.12.024_bib0003","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-2007-1007183","article-title":"Antimitochondrial antibodies in primary biliary cirrhosis","volume":"17","author":"Leung","year":"1997","journal-title":"Semin Liver Dis"},{"issue":"4","key":"10.1016\/j.dld.2024.12.024_bib0004","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1136\/gut.2003.036558","article-title":"Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis","volume":"54","author":"Rigopoulou","year":"2005","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.dld.2024.12.024_bib0005","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jhep.2004.11.016","article-title":"Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis","volume":"42","author":"Nakamura","year":"2005","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.dld.2024.12.024_bib0006","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1542-3565(04)00465-3","article-title":"Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?","volume":"2","author":"Yang","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.dld.2024.12.024_bib0007","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.21472","article-title":"Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis","volume":"45","author":"Nakamura","year":"2007","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.dld.2024.12.024_bib0008","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/hepr.12423","article-title":"Autoantibody status and histological variables influence biochemical response to treatment and long-term outcomes in Japanese patients with primary biliary cirrhosis","volume":"45","author":"Nakamura","year":"2015","journal-title":"Hepatol Res"},{"issue":"s3","key":"10.1016\/j.dld.2024.12.024_bib0009","doi-asserted-by":"crossref","first-page":"S412","DOI":"10.1111\/j.1872-034X.2007.00244.x","article-title":"Predictive role of anti-gp210 and anticentromere antibodies in long-term outcome of primary biliary cirrhosis","volume":"37","author":"Nakamura","year":"2007","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.dld.2024.12.024_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2169\/internalmedicine.50.4462","article-title":"Risk factors and prediction of long-term outcome in primary biliary cirrhosis","volume":"50","author":"Ishibashi","year":"2011","journal-title":"Int Med (Tokyo, 1992)"},{"issue":"1","key":"10.1016\/j.dld.2024.12.024_bib0011","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10238-008-0150-6","article-title":"The value of antinuclear antibodies in primary biliary cirrhosis","volume":"8","author":"Gao","year":"2008","journal-title":"Clin Exp Med"},{"issue":"3","key":"10.1016\/j.dld.2024.12.024_bib0012","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/gut.2005.075002","article-title":"Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis","volume":"55","author":"Rigamonti","year":"2006","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.dld.2024.12.024_bib0013","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1440-1746.1995.tb01597.x","article-title":"High prevalence of antibodies to recombinant CENP-B in primary biliary cirrhosis: nuclear immunofluorescence patterns and ELISA reactivities","volume":"10","author":"Parveen","year":"1995","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.dld.2024.12.024_bib0014","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.dld.2024.12.024_bib0015","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/apt.13927","article-title":"The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210","volume":"45","author":"Yang","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dld.2024.12.024_bib0016","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.jhep.2022.06.017","article-title":"Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis","volume":"77","author":"Corpechot","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.dld.2024.12.024_bib0017","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"Hirschfield","year":"2017","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.dld.2024.12.024_bib0018","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.dld.2024.12.024_bib0019","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.dld.2024.12.024_bib0020","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.dld.2024.12.024_bib0021","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.dld.2024.12.024_bib0022","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12072-023-10587-w","article-title":"Prognostic significance of liver stiffness in patients with primary biliary cholangitis: validation of Baveno VII criteria","volume":"18","author":"Ding","year":"2024","journal-title":"Hepatol Int"},{"issue":"2","key":"10.1016\/j.dld.2024.12.024_bib0023","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group","volume":"24","author":"Bedossa","year":"1996","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.dld.2024.12.024_bib0024","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/hep4.1907","article-title":"Immunoglobulin M: a neglected serum biomarker in treatment-naive primary biliary cholangitis with normal alkaline phosphatase","volume":"6","author":"Ding","year":"2022","journal-title":"Hepatol Commun"},{"issue":"5","key":"10.1016\/j.dld.2024.12.024_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101121","article-title":"Anti-gp210-positive primary biliary cholangitis: the dilemma of clinical treatment and emerging mechanisms","volume":"28","author":"Wang","year":"2023","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.dld.2024.12.024_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1098076","article-title":"Using two-step cluster analysis to classify inpatients with primary biliary cholangitis based on autoantibodies: a real-world retrospective study of 537 patients in China","volume":"13","author":"Zhao","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.dld.2024.12.024_bib0027","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.clinre.2013.04.005","article-title":"Diagnostic and clinical significance of anti-centromere antibodies in primary biliary cirrhosis","volume":"37","author":"Liberal","year":"2013","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"8","key":"10.1016\/j.dld.2024.12.024_bib0028","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1007\/s10067-021-05657-z","article-title":"The clinical and laboratory features associated with cancer in patients with primary biliary cholangitis: a longitudinal survey\u2013based study","volume":"40","author":"Bian","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.dld.2024.12.024_bib0029","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1572-0241.2003.07257.x","article-title":"Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis","volume":"98","author":"Muratori","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.dld.2024.12.024_bib0030","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/hep.21172","article-title":"Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis","volume":"43","author":"Wesierska-Gadek","year":"2006","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.dld.2024.12.024_bib0031","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/apt.14010","article-title":"Editorial: scoring systems in primary biliary cholangitis \u2013 time to make a move. Authors\u2019 reply","volume":"45","author":"Yang","year":"2017","journal-title":"Aliment Pharmacol Therapeut"},{"key":"10.1016\/j.dld.2024.12.024_bib0032","series-title":"Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases","author":"Lindor","year":"2018"},{"issue":"12","key":"10.1016\/j.dld.2024.12.024_bib0033","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1002\/hep4.2103","article-title":"Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid","volume":"6","author":"Ding","year":"2022","journal-title":"Hepatol Commun"},{"issue":"9","key":"10.1016\/j.dld.2024.12.024_bib0034","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.gastrohep.2023.01.001","article-title":"Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid","volume":"46","author":"Ding","year":"2023","journal-title":"Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.dld.2024.12.024_bib0035","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/apt.17226","article-title":"Liver transplant-free survival according to alkaline phosphatase andGLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid","volume":"56","author":"de Veer","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.dld.2024.12.024_bib0036","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.14309\/ajg.0000000000002238","article-title":"Effectiveness of fenofibrate in treatment-naive patients with primary biliary cholangitis: a randomized clinical trial","volume":"118","author":"Liu","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"000","key":"10.1016\/j.dld.2024.12.024_bib0037","doi-asserted-by":"crossref","first-page":"000","DOI":"10.14218\/JCTH.2022.00058","article-title":"An-Luo-Hua-Xian pill improves the regression of liver fibrosis in chronic hepatitis b patients treated with entecavir","volume":"000","author":"Liu","year":"2022","journal-title":"J Clin Transl Hepatol"},{"issue":"6","key":"10.1016\/j.dld.2024.12.024_bib0038","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.jhep.2022.07.018","article-title":"Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B","volume":"77","author":"Ji","year":"2022","journal-title":"J Hepatol"},{"issue":"19","key":"10.1016\/j.dld.2024.12.024_bib0039","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.3748\/wjg.v11.i19.2892","article-title":"Multicenter clinical study on Fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis B","volume":"11","author":"Liu","year":"2005","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.dld.2024.12.024_bib0040","article-title":"Low-risk individuals with primary biliary cholangitis and significant liver stiffness: prognosis and treatment","author":"Ding","year":"2024","journal-title":"Hepatol Int"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865824011502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865824011502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T02:52:38Z","timestamp":1742957558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865824011502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1590865824011502"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2024.12.024","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The prognostic value of anti-gp210 and anti-centromere antibodies in patients with primary biliary cholangitis: Enhancing the prognostic utility on the GLOBE scoring system","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2024.12.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}